Application of Neogenin in preparation of medicine for preventing, relieving and/or treating myocardial infarction and related diseases thereof

A technology for myocardial infarction and ischemic cardiomyopathy, applied in the relief and/or treatment of drugs for myocardial infarction and its related diseases, multi-functional transmembrane receptor neogenin, in the field of preparation and prevention, can solve problems such as unclear effects , achieve the effect of improving heart function, significant protection, and reducing myocardial remodeling

Pending Publication Date: 2022-08-02
WUHAN UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the role of Neo1 in myocardial infarction remains unclear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Neogenin in preparation of medicine for preventing, relieving and/or treating myocardial infarction and related diseases thereof
  • Application of Neogenin in preparation of medicine for preventing, relieving and/or treating myocardial infarction and related diseases thereof
  • Application of Neogenin in preparation of medicine for preventing, relieving and/or treating myocardial infarction and related diseases thereof

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0028] Experimental Example 1 Neo1 neutralizing antibody aggravates cardiac function after myocardial infarction

[0029] 1. Inject Neo1 neutralizing antibody

[0030]Neo1 neutralizing antibody (Cat. No. AF1079) was purchased from RD Company in the United States. It can effectively bind to the receptor Neo1, block the interaction between Neo1 and its related ligands, and complete the inhibition of Neo1 function in vivo. 2 hours before myocardial infarction, the mice were fixed, and Neo1 neutralizing antibody (the solvent was normal saline) was injected through the tail vein at a dose of 2 μg / mouse, and the control group was given a placebo (vehicle, normal saline). The experiment was divided into 4 groups according to the principle of randomization and blinding: no operation (sham)+vehicle, sham+Anti-Neo1, myocardial infarction group (MI)+vehicle, MI+Anti-Neo1.

[0031] 2. Obtaining the myocardial infarction model

[0032] (1) Anesthetize by intraperitoneal injection of 3% s...

experiment example 2

[0042] Experimental Example 2 Neo1 neutralizing antibody increases infarct size and aggravates myocardial remodeling after myocardial infarction

[0043] 1. 2,3,5-Triphenyltetrazolium chloricej (TTC) staining

[0044] (1) After the mice were sacrificed 3 days after myocardial infarction, the cardiac tissue was quickly taken out and placed in a 10% KCl solution.

[0045] (2) After washing the heart, place it in a -20°C refrigerator for 30 minutes.

[0046] (3) Take out the heart tissue, cut it into slices evenly along the long axis of the heart from the apex to the bottom of the heart, immediately place the slices in 10 mL of 2% TTC solution, and incubate at 37°C for 20 min. Normal cardiac tissue stained bright red, while the infarcted area was pale.

[0047] (4) Fix the brain tissue sections with 10% neutral formalin solution, take a general picture, and calculate the infarct size.

[0048] 2. Evaluation of myocardial remodeling after myocardial infarction

[0049] 2.1 Det...

experiment example 3

[0110] Experimental Example 3Neo1 Neutralizing Antibody Aggravated Cardiomyocyte Apoptosis After Myocardial Infarction

[0111] 3.1 Western blot monitoring of apoptosis-related proteins

[0112] Protein extraction, electrophoresis gel as above, using primary antibodies Bax, Bcl-2 and GAPDH.

[0113] 3.2 Immunofluorescence

[0114] 3.2.1 Preparation of paraffin specimens and sections

[0115] (1) The mouse heart tissue was removed from the 10% formalin solution, the heart tissue was trimmed in a fume hood, and the trimmed heart tissue and the corresponding label were placed in a dehydration box.

[0116] (2) Dehydration and wax dipping: Put the dehydration box into the dehydrator for dehydration and wax dipping. 75% ethanol (4h)→85% ethanol (2h)→90% ethanol (2h)→95% ethanol (1h)→anhydrous ethanol I (30min)→anhydrous ethanol II (30min)→alcohol benzene (5-10min) )→Xylene I (5-10min)→Xylene II (5-10min)→65°C melted paraffin I (1h)→65°C melted paraffin II (1h)→65°C melted paraf...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of Neogenin in preparation of medicines for preventing, relieving and / or treating myocardial infarction and related diseases thereof, and belongs to the field of functions and application of genes. Research finds that a Neogenin (Neo1) neutralizing antibody or over-expression of Neo1 can aggravate or relieve myocardial remodeling, deterioration or improve cardiac functions after myocardial infarction, and shows that Neo1 has a protective effect in myocardial infarction, and Neo1 can be used for preparing medicines for preventing, relieving and / or treating myocardial infarction and related diseases by taking Neo1 as a target spot or Neo1. Wherein the myocardial infarction and related diseases comprise acute ST segment elevation type myocardial infarction, acute non-ST segment elevation type myocardial infarction, ischemic cardiomyopathy, heart failure and the like; according to the pharmaceutical application, Neo1, a Neo1 activating agent or a substance for promoting Neo1 expression is used as a medicine. The invention provides a new medicine for preventing, relieving and / or treating myocardial infarction.

Description

technical field [0001] The invention belongs to the field of gene function and application, and relates to a multifunctional transmembrane receptor neogenin (Neo1) of the immunoglobulin superfamily. Application of Myocardial Infarction and Related Disease Drugs. Background technique [0002] Myocardial infarction (MI for short) refers to the persistent ischemia and hypoxia of myocardial cells caused by a sharp reduction or interruption of coronary blood flow, which eventually leads to irreversible necrosis of myocardial cells. At present, the significant increase in the rate of emergency PCI in my country has not significantly curbed the increase in mortality, and the quality of life of patients after myocardial infarction is still not optimistic [1]. Pathological myocardial remodeling after myocardial infarction can lead to adverse events such as malignant arrhythmia, heart failure and sudden death, and is an important factor affecting the prognosis of patients with myocar...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A61K45/00A61P9/10
CPCA61K38/1774A61K45/00A61P9/10
Inventor 万军王梦龙张记收徐瑶赵蒙蒙刘剑芳于君平徐姝婉潘威叶晶王震叶迪冯勇淇
Owner WUHAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap